Recent Advances in Aptamer Discovery and Applications.
Zhang Y, Lai BS, Juhas M. · 2019
Read Recent Advances in Aptamer Discovery and Applications. by Zhang Y, Lai BS, Juhas M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6429292.txt.
Introduction
Zhang and co-authors review recent progress with aptamers, short strands of DNA, RNA, or synthetic XNA that fold to grip a chosen target tightly. Labs create them through SELEX, a selection process that fishes the best binders out of vast random pools. Their uses already span basic research, food safety checks, and environmental monitoring.
Newer selection methods get the most attention, followed by applications in biosensing, biotechnology, and medicine, where aptamers serve as diagnostics and as drugs in their own right. Against antibodies they offer faster production, lower cost, and no batch variation. Remaining limits concern targeted delivery and real-time detection, and the closing sections map where developers are pushing next.
Catalog record
| CREATOR | Zhang Y, Lai BS, Juhas M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Recent Advances in Aptamer Discovery and Applications By Yang Zhang, Bo Shiun Lai, Mario Juhas, Laura Cerchia Published in: Molecules DOI: 10.3390/molecules24050941 ABSTRACT Abstract Aptamers are short, single-stranded DNA, RNA, or synthetic XNA molecules that can be developed with high affinity and specificity to interact with any desired targets. They have been widely used in facilitating discoveries in basic research, ensuring food safety and monitoring the environment. Furthermore, aptamers play promising roles as clinical diagnostics and therapeutic agents. This review provides update on the recent advances in this rapidly progressing field of research with particular emphasis on generation of aptamers and their applications in biosensing, biotechnology and medicine. The limitations and future directions of aptamers in target specific delivery and real-time detection are also discussed. Keywords: aptamer, systematic evolution of ligands by exponential enrichment (SELEX), diagnostics, therapeutics, biosensor, nanorocket 1. INTRODUCTION Target-specific therapy was discovered by the inventor of chemotherapy, Paul Ehrlich [1]. The ensuing development of hybridoma technology for generating monoclonal antibodies, which realized Ehrlich’s vision [2], along with the therapeutic success of antibodies led to the development of a number of novel antibody drugs. The examples of these drugs include trastuzumab targeting receptor tyrosine-protein kinase 2 ERBB2 implicated in ovarian and breast tumors [3], anti-CD20 chimeric mAb rituximab developed for treating B-cell non-Hodgkin lymphoma [4], and Vedolizumab inhibiting integrin α4β7, which plays an important role in ulcerative colitis and Crohn’s disease [5]. The idea to use nucleic acids to recognize protein targets only emerged later as a result of HIV research. It was shown that the trans-acting response element (TAR)-containing RNA sequences can inhibit HIV replication with high affinity and specificity [6]. Aptamers are short, single-stranded oligonucleotides (DNA or RNA) that bind to targets with high affinity and specificity by folding into tertiary structures [7,8]. Aptamers have been extensively used in basic research, to ensure food safety and to monitor the environment. Furthermore, aptamers have promising role in clinical diagnostics and as therapeutic agents. Although aptamers recognize and bind targets of interest just like antibodies, they have a number of advantages, such as shorter generation time, lower costs of manufacturing, no batch-to-batch variability, higher modifiability, better thermal stability and higher target potential ranging from ions to live animals (Table 1). A more thorough comparison of aptamers and antibodies was reviewed by Zhou and Rossi [9]. Our review provides an update on recent advances in the field of aptamers with particular focus on the methods of generating novel aptamers and the applications of aptamers in biosensing, biotechnology and biomedicine. [Table: Comparison between aptamers and antibodies. A comparison of critical features of aptamers shows how aptamers can supplement monoclonal antibodies.] 2. GENERATION OF APTAMERS A number of approaches were developed in recent years to generate aptamers more reliably and efficiently. These include the systematic evolution of ligands by exponential Enrichment (SELEX) approach and its variations, such as immunoprecipitation-coupled SELEX (IP-SELEX), capture-SELEX, cell-SELEX, capillary electrophoresis-SELEX (CE-SELEX), atomic force microscopy-SELEX (AFM-SELEX), and artificially expanded genetic information system-SELEX (AEGIS-SELEX), which are herein reviewed. The key aspects, advantages, and disadvantages of each SELEX method [9,10,11,12] are highlighted in Table 2. [Table: Key aspects, advantages, and disadvantages of the currently used SELEX methods.] 2.1. Systematic Evolution of Ligands by EXponential Enrichment (SELEX) SELEX is a standard method of generating aptamers, where the target of interest is first incubated with a pool of 1014~1016 single-stranded random oligonucleotides. Oligonucleotides in the SELEX library typically consist of 40~100 nucleotides, which harbor a random region in the middle and fixed sequences on both ends. Subsequently, the target-binding oligonucleotides are separated from the unbound ones. The bound DNA oligomers are then eluted and amplified by PCR. After several rounds of selection, the resulting DNA sequences (aptamers) with high affinity and specificity are enriched in the pool and sequenced (Figure 1) [7,8]. The most common modifications toward traditional SELEX method aimed to simplify the SELEX procedure or to generate improved aptamers include changing binding conditions, platform on which the selection is performed, type of target, library design and immobilization matrix. Besides DNA libraries, RNA libraries have also been successfully used for SELEX [9,13,14]. The differences in the majority of RNA SELEX protocols compared to DNA SELEX include the requirement of the protection of RNA from RNAases, amplification by T7 RNA polymerase and reverse transcription step before PCR. Consequently, the 5′-primer used for RNA SELEX usually encodes a promoter for T7 RNA polymerase [13]. [Figure: Schematic representation of SELEX (Systematic Evolution of Ligands by EXponential Enrichment). The starting single-stranded DNA or RNA library (1014~1016 random oligonucleotides) is composed of sequences 20~100 nucleotides in length with a random region in the middle flanked by fixed primer sequences. After incubation with the target of interest, the bound oligonucleotides are partitioned from unbound sequences and amplified by PCR. The resulting enriched DNA pool is used for the next round of selection.] 2.2. Immunoprecipitation-Coupled SELEX (IP-SELEX) The affinity and specificity of aptamers largely depend on their targets’ three-dimensional structures. As the three-dimensional targets of artificial, recombinant proteins can differ from their native conformation, it is suggested that the in vitro selection of aptamers might not be the best approach to select aptamers with the highest affinity and specificity under the standard physiological conditions [15]. IP-SELEX was developed to address this issue. Although IP-SELEX is comparable to the traditional SELEX method, it includes immunoprecipitation step to pull down the desirable targets in their native form. This leads to the enrichment for aptamers that retain the ability to recognize proteins under the normal physiological conditions. In the first round of IP-SELEX selection, cells harboring the protein of interest are incubated with ssDNA library in the suitable buffer and condition. Subsequently, cells are lysed, and the target protein is immunoprecipitated using antibody-coated beads. Following several rounds of washing, the protein-aptamer complexes are eluted from the beads and DNA sequences are PCR amplified for the next round of selection. The process of selection for the oligonucleotides with the high specificity and affinity against a desired target is repeated, thus leading to their final enrichment in the aptamer pool. The selected aptamers are then identified by sequencing [16]. IP-SELEX has been successfully used for the identification of anti-CD8 aptamers [17,18]. 2.3. Capture-SELEX In comparison to most SELEX methods, which require immobilization of targets on a solid surface, Capture-SELEX is used for a soluble small molecule targets. Capture-SELEX utilizes a special DNA library harboring fixed domain in the center flanked by two random domains, each of which is flanked by primer-binding sequences. As the fixed domain in the center is designed to be complementary to a biotinylated antisense oligonucleotide, this allows immobilization of the DNA library onto avidin-coated beads by hybridization. Aptamers that are able to form complexes with their targets detach from beads and solubilize, which allows their collection and PCR amplification [19]. Capture-SELEX strategy has been used successfully to select both DNA and RNA aptamers against small organic molecules in solution [20]. Furthermore, Capture-SELEX has been used recently to select aptamers against furaneol [21], penicillin [22], fluoroquinolone antibiotics [23], tobramycin, and other aminoglycoside antibiotics [24,25]. 2.4. Cell-SELEX In Cell-SELEX, live cells are used to select aptamers [26]. Cell-SELEX is considered to have practical applications particularly in oncology, as this approach